Silexion Closes $2.5M Public Offering with Warrants and Converts Sponsor Note
SLXN is trading near its 52-week low of $0.411 (12% above the low).
Summary
Silexion Therapeutics closed a $2.5 million public offering of shares and warrants, converted $750,001 of debt into equity, and now estimates shareholders' equity at $3.2 million.
Key Events · Financing and Capital Events · SLXN
-
Public Offering Closed
A public offering of 2,028,619 ordinary shares, 1,817,542 pre-funded warrants, and 3,846,161 Series E ordinary warrants at $0.65 per unit closed, raising approximately $2.5 million in gross proceeds.
-
Sponsor Note Converted
The company converted $750,001 of the Sponsor Note held by Moringa Sponsor, L.P. into 1,153,848 ordinary shares at $0.65 per share, reducing the note balance to $206,462.
-
Pre-Funded Warrants Exercised
Prior to closing, 823,770 pre-funded warrants were exercised, adding to the share count and further diluting existing shareholders.
-
Estimated Shareholders' Equity
After giving effect to the offering, note conversion, and warrant exercises, the company estimates shareholders' equity at approximately $3.2 million as of June 30, 2026, adjusted.
Analysis · SLXN · Life Sciences
On August 13, 2026, Silexion Therapeutics closed a $2.5 million public offering, issuing 2,028,619 ordinary shares, 1,817,542 pre-funded warrants, and 3,846,161 Series E ordinary warrants at $0.65 per unit. The offering was priced at a premium to the current stock price of $0.4599, but the warrants and pre-funded warrants create significant potential dilution. The company also converted $750,001 of its Sponsor Note into 1,153,848 ordinary shares at the same $0.65 price, reducing the note balance to $206,462. The net proceeds of approximately $2.1 million will fund the SIL204 clinical trial and general corporate purposes. This capital raise is critical for a company with a going concern warning and a market cap of only $489,033, but the dilutive structure and low share price reflect the company's distressed position.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $0.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $489K. The 52-week trading range was $0.41 to $80.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.